Reversing an amphetamine-induced laboratory change can help screen a candidate drug without establishing clinical efficacy. A rat study tested whether the experimental neurotensin receptor agonist NT69L continued to affect prepulse inhibition after 21 days of treatment. The authors reported no demonstrated loss of its effect under the studied conditions.
The tolerance question concerned NT69L’s action, not whether the rats became generally tolerant to amphetamine. This distinction is essential to reading the result.
What is prepulse inhibition?
Prepulse inhibition, or PPI, describes the reduction in a startle response when a weaker stimulus shortly precedes a stronger one. Briody and colleagues used acoustic stimuli: a 120-dB startle pulse, preceded on selected trials by a brief sound 4, 8 or 12 dB above a continuous 65-dB background.
The prepulse began 100 milliseconds before the startle pulse. PPI was calculated from the ratio of startle magnitude on paired trials to startle magnitude on pulse-only trials. It is an operational measure of sensorimotor gating, not a diagnosis of schizophrenia or a direct measure of hallucinations, judgment or driving.
Which drugs were administered?
Sprague-Dawley rats received NT69L at 1 mg/kg, haloperidol at 1 mg/kg, or the relevant control injection. Treatments were subcutaneous, either acutely or daily for 21 days. On test days, d-amphetamine at 5 mg/kg subcutaneously followed pretreatment by 30 minutes; animals entered the startle chambers 20 minutes after the amphetamine challenge.
A separate experimental series used clozapine at 20 mg/kg and a serotonin-receptor challenge drug called DOI at 0.5 mg/kg. Here “DOI” is the compound abbreviation for a substituted amphetamine, not a digital object identifier. Its results should not be merged indiscriminately with the d-amphetamine condition.
The amphetamine series evaluated whether pretreatment altered a drug-induced PPI disruption. It did not reproduce a human course of stimulant-associated psychosis or measure recovery from one.
What did the amphetamine challenge show?
D-amphetamine disrupted PPI. Acute NT69L significantly blocked that disruption at all three tested prepulse intensities. After 21 daily NT69L injections, a significant blocking effect was reported at the 12-dB prepulse intensity.
The paper found no significant difference between NT69L’s day-one and day-21 blocking effects. Its averages across prepulse intensities also supported continued activity. The authors described the findings as absence of tolerance to this antipsychotic-like effect.
That conclusion should retain its endpoint and statistical limits. The chronic result was not significant at every individual intensity, and a nonsignificant day-one versus day-21 comparison does not independently prove exact equivalence.
A separate acute dose–response experiment estimated an NT69L ED50 of 0.08 mg/kg for blocking amphetamine-disrupted PPI. This was an effect estimate within an animal assay, not a human therapeutic dose.
How large and balanced were the groups?
The study combined a separate acute experiment with day-one observations from the chronic experiment. The chronic animals were retested on day 21, but the combined day-one group was therefore not identical to the day-21 group.
For example, the pulse-alone response table lists 28 animals for NT69L plus amphetamine on day one and ten on day 21. Haloperidol-plus-amphetamine groups contained four animals at each reported time. Other controls were larger, and dose–response groups were reported as having at least eight animals.
Those unequal denominators matter. A broad range of group sizes cannot be condensed into one large sample supposedly followed identically throughout the study.
Could changes in startle amplitude explain the PPI result?
The investigators examined pulse-alone responding as well as the calculated PPI percentage. NT69L reduced startle amplitude in some conditions, including saline-treated animals, yet did not appreciably change their PPI. D-amphetamine disrupted PPI without a significant pulse-alone difference from saline controls.
The authors argued that startle amplitude and PPI effects were not simply correlated. This assessment helps interpret the ratio-based endpoint, but it does not convert PPI into a comprehensive measure of behavior or toxicity.
Repeated pretreatment also produced no significant difference in body-weight gain from saline controls. That null result concerns one measured outcome; it is not a complete safety assessment.
Why is clinical translation limited?
These were rats receiving subcutaneous drugs under tightly controlled acoustic parameters. The paper discussed differing results from another amphetamine-PPI experiment and possible contributions from testing parameters and animal source. The assay’s outcome can depend on those details.
The proposed dopamine and serotonin mechanisms were interpretations supported by related work, not a demonstration that the same mechanism treats human illness. No human symptom, retention or adverse-event trial was conducted here.
The study supports continued investigation of an experimental compound and illustrates endpoint-specific tolerance. It cannot establish that NT69L was a proven human treatment, or that preventing one amphetamine-induced response prevents all stimulant-related harms.
Scientific source
Briody S, Boules M, Oliveros A, Fauq I, Richelson E. Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance. Behavioural Brain Research. 2010;207(1):118–124; electronically published October 2, 2009. doi:10.1016/j.bbr.2009.09.044. Full-text author manuscript. Historical original rat experiment.
Leave a Reply